Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80
Document › Details

Exquiron Biotech AG. (2/8/15). "Press Release: SAMDI Tech, Inc and Exquiron Announce Partnership Agreement". Chicago, IL.

Region Region EUR(WEST)+AM(NORTH)
Organisations Organisation Exquiron Biotech AG
  Group Evotec (Group)
  Organisation 2 SAMDI Tech Inc.
Products Product drug discovery services
  Product 2 MALDI-TOF mass spectrometry technology
Index term Index term Exquiron Biotech–SAMDI Tech: drug discovery services, 201502– collab mutually co-promotion of respective services in Europe + North America

SAMDI Tech and Exquiron are expanding their service offering by entering into a partnership agreement, allowing SAMDI Tech and Exquiron to mutually promote their respective services in Europe and North America. The two companies aim to offer hit discovery, hit profiling, and assay development services, combining their expertise to the benefit of their clients. The partnership provides SAMDI Tech’s clients the added benefit of Exquiron’s broad assay capabilities and lead-like, 250,000 compound collection as well as access of SAMDI Tech’s exclusive label-free, MALDI-TOF capabilities to Exquiron and its clients.

“I am excited to partner with Exquiron as our technology is innovative to the discovery field and coupled with Exquiron’s additional assay capabilities and compound collection we can offer a comprehensive solution to our clients.

SAMDI is a unique label-free assay platform for measurement of complex biochemical activity.

Stephan Fasler Ph.D., CEO of Exquiron commented “We have previously collaborated with SAMDI Tech; the company has been our first choice for entering into this partnership. We are impressed by the novelty and quality of SAMDI Tech’s label-free assay technology, which, coupled with their excellent assay development services, renders SAMDI Tech a company to absolutely work with.”

About SAMDI Tech, Inc:

SAMDI Tech, Inc, headquartered in Chicago, IL is a contract research organization supporting discovery research. SAMDI’s pioneering technology combines surface chemistry and MALDI mass spectrometry in both 384 and 1536 format for rapid assay development, high-throughput screening, and peptide substrate discovery and supports both biotech and large pharmaceutical companies. Learn more about SAMDI Tech at

About Exquiron Biotech AG:

Exquiron, headquartered in Reinach BL, Switzerland, is a company dedicated to contract research in early stage drug discovery. Its services span from assay development for hit finding and profiling purposes to compound selection, high throughput screening, selectivity testing and hit characterization, and SAR expansion. Exquiron’s team brings extensive skills and know-how in all areas of the hit identification process, including broad target class coverage, applicable technologies, data processing and evaluation.

Record changed: 2016-04-24


Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81

More documents for Evotec (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture [iito] Männer Ballett 650x80px

» top